Axsome Therapeutics (NASDAQ:AXSM) Now Covered by Wolfe Research

Wolfe Research began coverage on shares of Axsome Therapeutics (NASDAQ:AXSM) in a research note published on Monday, MarketBeat Ratings reports. The firm issued an outperform rating on the stock.

A number of other brokerages have also recently issued reports on AXSM. HC Wainwright upped their price objective on shares of Axsome Therapeutics from $200.00 to $260.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Wells Fargo & Company upped their price target on Axsome Therapeutics from $193.00 to $202.00 and gave the stock an “overweight” rating in a research note on Tuesday. UBS Group raised their price objective on Axsome Therapeutics from $248.00 to $251.00 and gave the company a “buy” rating in a research note on Tuesday. Oppenheimer reaffirmed an “outperform” rating and set a $220.00 target price on shares of Axsome Therapeutics in a research report on Wednesday, December 31st. Finally, Robert W. Baird set a $209.00 price target on shares of Axsome Therapeutics in a research report on Tuesday, January 13th. Seventeen equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $216.12.

Axsome Therapeutics Stock Down 2.8%

AXSM opened at $169.95 on Monday. The company has a market capitalization of $8.57 billion, a PE ratio of -46.06, a price-to-earnings-growth ratio of 12.57 and a beta of 0.40. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.57 and a quick ratio of 1.50. Axsome Therapeutics has a fifty-two week low of $86.99 and a fifty-two week high of $191.50. The business has a 50-day moving average of $174.91 and a 200-day moving average of $145.40.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Monday, February 23rd. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.70) by $0.14. The firm had revenue of $196.00 million for the quarter, compared to analyst estimates of $191.33 million. Axsome Therapeutics had a negative net margin of 28.69% and a negative return on equity of 251.47%. The company’s revenue was up 65.0% on a year-over-year basis. Equities research analysts forecast that Axsome Therapeutics will post -2.79 EPS for the current fiscal year.

Insider Buying and Selling at Axsome Therapeutics

In other news, CFO Nick Pizzie sold 12,000 shares of the stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $187.92, for a total value of $2,255,040.00. Following the completion of the transaction, the chief financial officer owned 42,588 shares in the company, valued at approximately $8,003,136.96. This represents a 21.98% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Mark E. Saad sold 37,577 shares of the firm’s stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $165.18, for a total transaction of $6,206,968.86. Following the transaction, the director owned 10,002 shares of the company’s stock, valued at approximately $1,652,130.36. This represents a 78.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 308,874 shares of company stock worth $51,390,805. Corporate insiders own 22.40% of the company’s stock.

Hedge Funds Weigh In On Axsome Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AXSM. Virtu Financial LLC acquired a new stake in shares of Axsome Therapeutics during the fourth quarter worth approximately $2,844,000. Invesco Ltd. increased its holdings in Axsome Therapeutics by 28.6% during the 4th quarter. Invesco Ltd. now owns 1,273,494 shares of the company’s stock valued at $232,591,000 after purchasing an additional 282,937 shares in the last quarter. Strive Financial Group LLC bought a new position in Axsome Therapeutics in the 4th quarter valued at $62,000. Ameriflex Group Inc. acquired a new position in Axsome Therapeutics in the fourth quarter worth $37,000. Finally, Mercer Global Advisors Inc. ADV grew its holdings in shares of Axsome Therapeutics by 64.2% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 3,222 shares of the company’s stock worth $588,000 after purchasing an additional 1,260 shares during the last quarter. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Revenue and commercial strength — Q4 sales jumped roughly 65% year‑over‑year and full‑year 2025 revenue rose strongly, led by Auvelity and Sunosi, beating consensus revenue estimates and showing solid commercial traction. AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
• Positive Sentiment: Pipeline progress — Axsome dosed the first patient in the CLARITY Phase 3 trial of solriamfetol for MDD with excessive daytime sleepiness, adding a near‑term clinical catalyst. Axsome Therapeutics Initiates CLARITY Phase 3 Trial
• Positive Sentiment: Analyst support — Needham reaffirmed a Buy and set a $225 price target, signaling continued bull case and upside potential. Benzinga coverage of Needham rating
• Neutral Sentiment: Earnings materials and call — Management released the Q4 / FY2025 results, slide deck and earnings call transcript; these provide detail behind the revenue beat and guidance/comments for investors to review. Axsome press release / slide deck
• Neutral Sentiment: Mixed EPS reporting — several outlets summarized Q4 results and call highlights (transcript and summaries available), useful for investors but containing varying EPS figures across reports. AXSM Q4 2025 Earnings Call Highlights
• Negative Sentiment: Profitability and accounting headlines — despite revenue strength, Axsome remains loss‑making (negative net margins and a large negative ROE); some reports flagged a wider per‑share loss in certain metrics, creating near‑term investor concern. Axsome Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: Valuation and pipeline skepticism — some analysts and commentators argue the pipeline may be overvalued and commercial uptake risks remain, tempering enthusiasm despite upside price targets. Axsome: Q4 Earnings Review — Pipeline May Be Overvalued

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.